# LYNAVOY
> **NDA220295** · New Drug Application · Sponsor: GLAXOSMITHKLINE · Approved 2026-03-17
## Drug
- **FDA Application Number:** NDA220295
- **Application type:** New Drug Application
- **Brand name:** LYNAVOY
- **Generic name:** Linerixibat
- **Active ingredients:** LINERIXIBAT
- **Dosage form:** TABLET
- **Route:** ORAL
- **Marketing status:** Prescription
- **Sponsor:** GLAXOSMITHKLINE
- **First approval:** 2026-03-17
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220295)
---
*MORVS · CC0 1.0*